UBS Group set a GBX 1,460 ($19.07) price target on GlaxoSmithKline (LON:GSK) in a research report released on Monday morning, Borsen Zeitung reports.
Other analysts also recently issued research reports about the company. Jefferies Financial Group set a GBX 1,925 ($25.15) price objective on GlaxoSmithKline in a research report on Wednesday, July 28th. Liberum Capital reiterated a buy rating and issued a GBX 1,700 ($22.21) price objective on shares of GlaxoSmithKline in a research report on Wednesday, July 7th. Libertas Partners reiterated a buy rating and issued a GBX 1,700 ($22.21) price objective on shares of GlaxoSmithKline in a research report on Wednesday, June 16th. JPMorgan Chase & Co. set a GBX 1,300 ($16.98) target price on GlaxoSmithKline in a report on Wednesday, July 28th. Finally, Credit Suisse Group set a GBX 1,400 ($18.29) target price on GlaxoSmithKline in a report on Thursday, July 29th. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, GlaxoSmithKline has a consensus rating of Hold and an average price target of GBX 1,541.21 ($20.14).
Shares of GSK stock opened at GBX 1,414 ($18.47) on Monday. The stock has a 50 day moving average of GBX 1,446.04 and a two-hundred day moving average of GBX 1,383.86. The company has a current ratio of 0.82, a quick ratio of 0.52 and a debt-to-equity ratio of 118.10. GlaxoSmithKline has a 12 month low of GBX 1,190.80 ($15.56) and a 12 month high of GBX 1,528.80 ($19.97). The company has a market capitalization of £71.15 billion and a P/E ratio of 16.29.
GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.